However, in a cohort study of patients with advanced NSCLC, higher levels of FoxP3+ Treg cells and TGF-β were associated with favorable clinical response to anti-PD-1 immunotherapy (124). Here, PDCD1 is linked to non-small cell lung carcinoma.